Biotech Values

[jq1234]

However I am curious why GSK decided to give up US rights. Do they think that Amigal monotherapy is a small market?

GSK had to give up something to get the new deal done. I think GSK got a good deal here, not only changed cost share from 25-75 to 40-60, but also in effect had FOLD to share risk with co-formulation with JCR's unproven ERT. Co-formulation can't go to phase 3 directly, they'll have to start from phase 1, plus most likely phase 3 will be against active comparator, currently approved ERT rather than placebo. In previous deal, FOLD share risk on their own drug only with either monotherapy or combination with approved ERTs.